UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.87 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 48.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 218,588 shares of the biopharmaceutical company's stock after buying an additional 70,904 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.14% of Ocular Therapeutix worth $1,867,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of OCUL. MetLife Investment Management LLC lifted its stake in Ocular Therapeutix by 2.7% in the fourth quarter. MetLife Investment Management LLC now owns 92,734 shares of the biopharmaceutical company's stock worth $792,000 after acquiring an additional 2,454 shares during the period. Teacher Retirement System of Texas grew its stake in shares of Ocular Therapeutix by 10.0% during the 4th quarter. Teacher Retirement System of Texas now owns 27,777 shares of the biopharmaceutical company's stock valued at $237,000 after purchasing an additional 2,526 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Ocular Therapeutix by 3.3% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,463 shares of the biopharmaceutical company's stock valued at $755,000 after buying an additional 2,853 shares in the last quarter. Cetera Investment Advisers lifted its holdings in Ocular Therapeutix by 0.6% in the 4th quarter. Cetera Investment Advisers now owns 723,840 shares of the biopharmaceutical company's stock worth $6,182,000 after purchasing an additional 4,342 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in shares of Ocular Therapeutix by 1.0% during the 4th quarter. Wellington Management Group LLP now owns 467,352 shares of the biopharmaceutical company's stock worth $3,991,000 after acquiring an additional 4,488 shares in the last quarter. Institutional investors own 59.21% of the company's stock.

Analyst Upgrades and Downgrades

OCUL has been the topic of a number of recent research reports. HC Wainwright reissued a "buy" rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Thursday, May 29th. Needham & Company LLC cut their price objective on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Royal Bank of Canada assumed coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 target price for the company. William Blair assumed coverage on shares of Ocular Therapeutix in a research note on Tuesday, April 8th. They set an "outperform" rating for the company. Finally, JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $16.25.

Ocular Therapeutix Price Performance

Shares of Ocular Therapeutix stock traded down $0.09 during trading hours on Wednesday, reaching $8.82. 13,528,782 shares of the company's stock were exchanged, compared to its average volume of 1,466,237. Ocular Therapeutix, Inc. has a 1 year low of $4.83 and a 1 year high of $11.78. The company has a market capitalization of $1.41 billion, a P/E ratio of -6.68 and a beta of 1.42. The business has a fifty day moving average of $7.60 and a two-hundred day moving average of $7.90. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19.

Insider Buying and Selling at Ocular Therapeutix

In related news, Director Richard L. Md Lindstrom acquired 10,000 shares of the business's stock in a transaction dated Thursday, May 8th. The shares were acquired at an average cost of $6.96 per share, for a total transaction of $69,600.00. Following the acquisition, the director now directly owns 172,704 shares in the company, valued at approximately $1,202,019.84. The trade was a 6.15% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Pravin Dugel sold 21,219 shares of the stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $7.18, for a total transaction of $152,352.42. Following the completion of the sale, the insider now directly owns 3,499,099 shares of the company's stock, valued at $25,123,530.82. This trade represents a 0.60% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 29,079 shares of company stock valued at $208,739 over the last 90 days. 2.30% of the stock is owned by insiders.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.